NCT06187831

Brief Summary

Central venous catheters are essential when administering treatment for hematological conditions. Many patients have a decreased platelet count which increases the risk for bleeding complications. Baarle et al. recently published a randomized controlled study where withholding prophylactic platelet transfusions before CVC placement in patients with a platelet count of 10,000 to 50,000 per cubic millimeter did not meet the predefined margin for non-inferiority for postprocedural bleeding events (PMID: 37224197). However, bleedings grade 2 (defined as bleeding that requires external compression) were included despite lacking clinical significance. The aim of the present study is to investigate whether lowering the preprocedural platelet transfusion trigger from 50x10\^9/L to 10x10\^9/L for insertions of central venous catheters remains safe with regards to postprocedural bleeding events of grade 3-4.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
927

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Feb 2024

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 17, 2023

Completed
17 days until next milestone

First Posted

Study publicly available on registry

January 3, 2024

Completed
2 months until next milestone

Study Start

First participant enrolled

February 26, 2024

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 17, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 17, 2026

Completed
Last Updated

May 1, 2026

Status Verified

April 1, 2026

Enrollment Period

2.1 years

First QC Date

December 17, 2023

Last Update Submit

April 27, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Incidence of bleeding events grade 3 and 4

    Incidence of bleeding events grade 3 and 4 according to the National Cancer Institute Common Terminology criteria for Adverse events (CTCAE), version 5.0.

    Up to 24 hours after insertion of a central venous catheter

Secondary Outcomes (3)

  • Incidence of bleeding events grade 2

    Up to 24 hours after insertion of a central venous catheter

  • Number of patients receiving pre-procedural platelet transfusion Number of patients receiving pre-procedural platelet transfusion

    From 24 hours before to 24 hours after insertion of a central venous catheter

  • Number of preprocedural units of platelet transfusions

    From 24 hours before to 24 hours after insertion of a central venous catheter

Study Arms (2)

Before the change of the departmental pre-procedural platelet transfusion trigger for CVC placement

Patients ≥18 years of age admitted to a hematological ward at the current department, with an indication for CVC placement will be eligible for inclusion in the study

After the change of the departmental pre-procedural platelet transfusion trigger for CVC placement

Patients ≥18 years of age admitted to a hematological ward at the current department, with an indication for CVC placement will be eligible for inclusion in the study

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients ≥18 years of age admitted to a hematological ward at the current department, with an indication for CVC placement, will be eligible for inclusion in the study.

You may qualify if:

  • ≥ 18 years of age
  • Indication for central venous catheter placement.
  • Patients admitted to a hematological ward at the current department

You may not qualify if:

  • Death within 24h after insertion of CVC.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Thomas Kander

Lund, Lunds Universitet, 22650, Sweden

Location

MeSH Terms

Conditions

HemorrhageThrombocytopeniaHematologic Diseases

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and SymptomsBlood Platelet DisordersHemic and Lymphatic DiseasesCytopenia

Study Officials

  • Thomas Kander, PhD

    Region Skåne Sweden

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
OTHER
Target Duration
2 Days
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

December 17, 2023

First Posted

January 3, 2024

Study Start

February 26, 2024

Primary Completion

March 17, 2026

Study Completion

March 17, 2026

Last Updated

May 1, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will share

Upon reasonable request, de-identified individual participant data from this clinical trial will be shared to facilitate scientific collaboration.

Shared Documents
STUDY PROTOCOL, CSR
Time Frame
After the publication of the study up to 3 years after the publication of the study
Access Criteria
Researchers may submit requests through the specified channel, detailing the purpose and proposed analyses. Approved applicants will sign a data access agreement, ensuring responsible and transparent use of the data.

Locations